


Product Name	: Imlunestrant
Cat. No.	: PC-73421
CAS No.	: 2408840-26-4
Molecular Formula	: C ₂₉ H ₂₄ F ₄ N ₂ O ₃
Molecular Weight	: 524.516
Target	: Estrogen Receptor/ERR
Solubility	: 10 mM in DMSO



Biological Activity

Imlunestrant (LY3484356) is a potent, oral, selective **estrogen receptor** degrader (SERD) and pure estrogen receptor antagonist with K_i values of 0.64 nM and 2.8 nM against WT ER α and Y537S mutant ER α proteins, respectively.

LY 3484356 is a potent and highly efficient degrader of wild type ER α and Y537N mutant ER α proteins in cells, with IC₅₀ values 3.0 nM and 9.6 nM, respectively.

LY3484356 is also a potent inhibitor of ER α -mediated transcription in vitro and in vivo.

LY 3484356 inhibits cell proliferation in wild type ER α and ESR1 Y537N mutant breast cancer cell lines with IC₅₀ of 3 and 17 nM, respectively. LY3484356 has IC₅₀ of <100 nM against a panel of ER+ breast cancer cell lines.

LY3484356 has demonstrated sustained and prolonged target inhibition in ESR1 wild type (MCF7) and ESR1 Y537S mutant (ST941/C) xenograft tumors.

LY3484356 demonstrated significant tumor growth inhibition and tumor regressions in wild type ESR1 breast cancer xenograft models such as MCF7, T47D and ZR-75-1, as well as ESR1 mutant breast cancer PDX models.

LY3484356 has shown synergy or additivity in combination with CDK4/6 inhibitor abemaciclib, mTOR inhibitor everolimus and PIK3CA inhibitor alpelisib in inhibiting cell proliferation in ER+ breast cancer cell lines in vitro and tumor growth inhibition in relevant xenograft or PDX models in vivo.

References

Shripad V. Bhagwat, et al. *Cancer Res* (2021) 81 (13_Supplement): 1236.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com